Novocure (NVCR) | Financial Analysis & Statements
Novocure Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
174.4M
Gross Profit
132.2M
75.82%
Operating Income
-40.4M
-23.17%
Net Income
-24.5M
-14.05%
Balance Sheet Metrics
Total Assets
804.3M
Total Liabilities
463.9M
Shareholders Equity
340.5M
Debt to Equity
1.36
Cash Flow Metrics
Operating Cash Flow
-23.7M
Free Cash Flow
-22.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Novocure Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 655.4M | 605.2M | 509.3M | 537.8M | 535.0M |
| Cost of Goods Sold | 166.9M | 137.2M | 128.3M | 114.9M | 114.9M |
| Gross Profit | 488.5M | 468.0M | 381.1M | 423.0M | 420.2M |
| Gross Margin % | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% |
| Operating Expenses | |||||
| Research & Development | 224.5M | 209.6M | 223.1M | 206.1M | 201.3M |
| Selling, General & Administrative | 417.7M | 428.9M | 390.9M | 306.4M | 263.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 642.3M | 638.5M | 613.9M | 512.5M | 464.5M |
| Operating Income | -153.8M | -170.5M | -232.9M | -89.5M | -44.3M |
| Operating Margin % | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% |
| Non-Operating Items | |||||
| Interest Income | 12.9M | 22.7M | 19.6M | 11.0M | 791.0K |
| Interest Expense | 17.0M | 10.3M | 3.3M | 3.3M | 3.4M |
| Other Non-Operating Income | -4.3M | -717.0K | -797.0K | -3.5M | -4.0M |
| Pre-tax Income | -136.2M | -131.2M | -191.7M | -81.8M | -52.1M |
| Income Tax | -23.0K | 37.5M | 15.3M | 10.7M | 6.3M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -136.2M | -168.6M | -207.0M | -92.5M | -58.4M |
| Net Margin % | -20.8% | -27.9% | -40.6% | -17.2% | -10.9% |
| Key Metrics | |||||
| EBITDA | -100.2M | -108.9M | -176.7M | -64.4M | -34.4M |
| EPS (Basic) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
| EPS (Diluted) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
| Basic Shares Outstanding | 111471991 | 107834368 | 106391178 | 104660476 | 103433274 |
| Diluted Shares Outstanding | 111471991 | 107834368 | 106391178 | 104660476 | 103433274 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Novocure Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 93.5M | 163.8M | 240.8M | 115.3M | 208.8M |
| Short-term Investments | 354.1M | 796.1M | 669.8M | 854.1M | 728.9M |
| Accounts Receivable | 89.4M | 74.2M | 61.2M | 86.3M | 93.6M |
| Inventory | 41.1M | 35.1M | 38.2M | 29.4M | 24.4M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 646.7M | 1.1B | 1.0B | 1.1B | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 115.8M | 84.5M | 80.7M | 63.8M | 54.4M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 10.6M | 14.6M | 14.0M | 11.2M | 12.1M |
| Total Non-Current Assets | 157.6M | 134.2M | 111.7M | 80.1M | 66.0M |
| Total Assets | 804.3M | 1.2B | 1.1B | 1.2B | 1.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 122.2M | 105.1M | 94.4M | 85.2M | 72.6M |
| Short-term Debt | 11.7M | 566.1M | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 223.2M | 756.4M | 179.1M | 158.8M | 142.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 236.7M | 117.3M | 596.2M | 584.3M | 575.2M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | 18.0K | 18.0K | 148.0K | 166.0K |
| Total Non-Current Liabilities | 240.6M | 124.2M | 604.5M | 591.7M | 586.4M |
| Total Liabilities | 463.9M | 880.6M | 783.6M | 750.5M | 729.0M |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -1.3B | -1.2B | -985.5M | -778.5M | -685.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 340.5M | 360.2M | 362.5M | 441.2M | 410.5M |
| Key Metrics | |||||
| Total Debt | 248.4M | 683.4M | 596.2M | 584.3M | 575.2M |
| Working Capital | 423.5M | 350.2M | 855.3M | 952.8M | 930.9M |
Balance Sheet Composition
Novocure Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -136.2M | -168.6M | -207.0M | -92.5M | -58.4M |
| Depreciation & Amortization | 14.6M | 11.2M | 11.0M | 10.6M | 10.3M |
| Stock-Based Compensation | 104.8M | 160.0M | 115.6M | 107.0M | 94.9M |
| Working Capital Changes | -39.0M | -22.8M | 14.8M | -2.5M | 1.3M |
| Operating Cash Flow | -50.8M | -20.8M | -88.9M | 18.8M | 51.1M |
| Investing Activities | |||||
| Capital Expenditures | -26.6M | -42.9M | -27.1M | -21.4M | -24.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -821.1M | -875.4M | -1.0B | -1.3B | -1.1B |
| Investment Sales | 1.3B | 778.0M | 1.2B | 1.2B | 958.0M |
| Investing Cash Flow | 437.3M | -140.2M | 184.1M | -140.0M | -144.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 100.0M | 96.9M | - | 0 | 0 |
| Debt Repayment | -560.9M | -12.9M | -10.0K | -28.0K | -26.0K |
| Financing Cash Flow | -457.5M | 88.2M | 4.4M | 5.2M | 4.5M |
| Free Cash Flow | -75.7M | -69.2M | -100.4M | 9.4M | 58.6M |
| Net Change in Cash | -71.0M | -72.8M | 99.7M | -115.9M | -89.2M |
Cash Flow Trend
Novocure Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-10.32
Forward P/E
-10.49
Price to Book
4.04
Price to Sales
2.16
PEG Ratio
0.16
Profitability Ratios
Profit Margin
-20.79%
Operating Margin
-21.33%
Return on Equity
-38.89%
Return on Assets
-9.06%
Financial Health
Current Ratio
2.90
Debt to Equity
72.95
Beta
0.82
Per Share Data
EPS (TTM)
$-1.22
Book Value per Share
$3.03
Revenue per Share
$5.88
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NVCR | 1.5B | -10.32 | 4.04 | -38.89% | -20.79% | 72.95 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






